Advertisement

High Throughput Screening in the Twenty-First Century

  • Jeff W. PaslayEmail author
  • John E. Morin
  • Richard K. Harrison
Chapter
Part of the Topics in Medicinal Chemistry book series (TMC, volume 5)

Abstract

High throughput screening (HTS) has become the cornerstone of lead identification for small molecules in drug discovery during the last quarter century. The evolution of the sciences and technologies that have evolved as the foundation of modern HTS campaigns are complex and require multidisciplinary interactions. Innovations in integrated automated systems, reagent systems enabled by molecular biology, computational capabilities, and visualization tools have converged to provide sophisticated tools to HTS practitioners. The success of HTS in an organization does not rest solely with those performing HTS but is critically dependent on the interactions of biology and chemistry members of the multidisciplinary teams throughout the early discovery process. Thus a basic knowledge and understanding of the components and processes of HTS is a necessary requirement for effective communication in planning, executing, and analyzing an HTS campaign. This chapter addresses the key components of HTS campaigns, common approaches, and related issues that should be understood by those engaged in small molecule drug discovery.

Keywords

Assay development Automation Data management High throughput screening Statistics 

References

  1. 1.
    Andersen Consulting (1997) Re-inventing drug discovery: the quest for innovation and productivity. Anderson Consulting, LondonGoogle Scholar
  2. 2.
    Pereira DA, Williams JA (2007) Brit J Pharmacol 152:53CrossRefGoogle Scholar
  3. 3.
    Glossary of Screening Terms, Society of Biomolecular Sciences. www.sbsonline.com
  4. 4.
    Macarron R (2006) Drug Disc Today 11:277CrossRefGoogle Scholar
  5. 5.
    Major J (2002) Curr Drug Dev 7:31Google Scholar
  6. 6.
    Melnick JS, Janes J, Kim S, Chang JY, Sipes DG, Gunderson D, Jarnes L, Matzen JT, Garcia ME, Hood TL, Beigi R, Xia G, Harig RA, Asatryan H, Yan SF, Zhou Y, Gu XJ, Saadat A, Zhou V, King FJ, Shaw CM, Su AI, Downs R, Gray NS, Schultz PG, Warmuth M, Caldwell JS (2006) PNAS 103:3153CrossRefGoogle Scholar
  7. 7.
    Soloveva V, LaRocque J, McKillip E (2006) J Assoc Lab Auto 11:145CrossRefGoogle Scholar
  8. 8.
    Huang KS, Mark D, Gandenberger FU (2006) Methods Enzymol 414:589CrossRefGoogle Scholar
  9. 9.
    Shoichet BK (2006) Drug Disc Today 11:607CrossRefGoogle Scholar
  10. 10.
    Leder L, Freuler F, Forstner M, Mayr LM (2007) Curr Opin Drug Disc Devel 10:193Google Scholar
  11. 11.
    Bonetta L (2006) Nature 439:1017CrossRefGoogle Scholar
  12. 12.
    Cawkill D, Eaglestone SS (2007) Drug Disc Today 12:820CrossRefGoogle Scholar
  13. 13.
    McKillip E, Bracy-Johnson N, Soloveva V, LaRocque J, Morin J, Paslay J (2007) Bioprocess J 2:39CrossRefGoogle Scholar
  14. 14.
    Chen J, Lake MR, Sabet RS, Niforatos W, Pratt SD, Cassar SC, Xu J, Gopalakrishnan S, Pereda-Lopez A, Gopalakrishnan M, Holzman TF, Moreland RB, Walter KA, Faltynek CR, Warrior U, Scott VE (2007) J Biomol Screen 12:61CrossRefGoogle Scholar
  15. 15.
    Fornwald JA, Lu Q, Wang D, Ames RS (2007) Methods Mol Biol 388:95CrossRefGoogle Scholar
  16. 16.
    Perrin F (1929) Photochimie Ann Phys Ser 10:169CrossRefGoogle Scholar
  17. 17.
    Weber G (1952) Biochem J 51:145CrossRefGoogle Scholar
  18. 18.
    Dandliker WB, Feigen GA (1961) Biochem Biophys Res Commun 5:299CrossRefGoogle Scholar
  19. 19.
    Jolley ME (1981) J Anal Toxicol 5:236CrossRefGoogle Scholar
  20. 20.
    Jia Y, Quinn CM, Talanian RV (2007) Expert Opin Drug Disc 2:909CrossRefGoogle Scholar
  21. 21.
    Kumar R, Clark DS (2006) Curr Opin Chem Bio 10:162CrossRefGoogle Scholar
  22. 22.
    Yong J, Quinn CM, Kwak S, Talanian RB (2008) Curr Opin Drug Tech 5:59CrossRefGoogle Scholar
  23. 23.
    Zhang W, Shor B, Ker Y (2006) Protein Expr Purif 46:414CrossRefGoogle Scholar
  24. 24.
    Huss KL, Blonigen PE, Campbell RM (2007) J Biomol Screen 12:578CrossRefGoogle Scholar
  25. 25.
    Vogel KM, Zhong Z, Kun Bi K, Pollok BK (2008) Expert Opin Drug Disc 3:15CrossRefGoogle Scholar
  26. 26.
    Von Leoprechting A, Kumpf R, Menzel S, Reulle D, Griebel R, Valler MJ, Büttner FH (2004) J Biomol Screen 9:719CrossRefGoogle Scholar
  27. 27.
    Fields B (2001) Meth Mol Biol 151:495Google Scholar
  28. 28.
    Lombard C, Saulnier J, Wallach J (2005) Biochimie 87:265CrossRefGoogle Scholar
  29. 29.
    Livingston DC, Brocklehurst JR, Canon JF, Leytus SP, Werly JA, Peltz SW, Peltz GA, Mangel WF (1981) Biochemistry 20:4298CrossRefGoogle Scholar
  30. 30.
    George J, Teear ML, Norey CG, Burns DD (2003) J Biomol Screen 8:72CrossRefGoogle Scholar
  31. 31.
    Karvinen J, Elomaa A, Makinen M, Hakala H, Mukkala V, Peuralahti J, Hurskainen P, Hovinen J, Hemmila I (2004) Anal Biochem 325:317CrossRefGoogle Scholar
  32. 32.
    Levine LM, Michener ML, Toth M, Holwerda BC (1997) Anal Biochem 247:83CrossRefGoogle Scholar
  33. 33.
    Lin S, Bock CL, Gardner DB, Webster JC, Favata MF, Trzaskos JM, Oldenburg KR (2002) Anal Biochem 300:15CrossRefGoogle Scholar
  34. 34.
    Harrison RK, Lin S, Seidel HM, Zhang J, Zhang L, McGeehan GM (2002) Curr Med Chem Immunol Endocr Metab Agents 2:23CrossRefGoogle Scholar
  35. 35.
    Eglan R (2005) Front Drug Des Disc 1:97CrossRefGoogle Scholar
  36. 36.
    Ito S, Yoshimoto R, Miyamoto Y, Mitobe Y, Nakamura T, Ishihara A, MacNeill DJ, Kanatani A, Tokita S (2006) Eur J Pharmacol 529:40CrossRefGoogle Scholar
  37. 37.
    Kumar M, Hsiao K, Vidugiriene J, Goueli SA (2007) Assay Drug Dev Technol 5:237CrossRefGoogle Scholar
  38. 38.
    Persani L, Calebiro C, Bonomi M (2008) Nat Clin Pract Endocrinol Metab 3:180CrossRefGoogle Scholar
  39. 39.
    Evans L, Romeo DP (1977) Am J Bot 64:1170CrossRefGoogle Scholar
  40. 40.
    Dowless MS, Barbee JL, Borchert KM, Bocchinfuso WP, Houck KA (2005) J Pharmacol 512:9Google Scholar
  41. 41.
    Golla R, Seethala R (2002) J Biomol Screen 6:515CrossRefGoogle Scholar
  42. 42.
    Weber M, Muthusubramaniam L, Murray J, Hudak E, Kornienko O, Johnson EN, Strulovici B, Kunapuli P (2004) Assay Drug Dev Tech 5:39CrossRefGoogle Scholar
  43. 43.
    Trinquet E, Fink M, Bazin H, Grillet F, Maurin F, Bourrier E, Ansanay H, Leroy C, Michaud A, Durroux T, Maurel D, Malhaire F, Goudet C, Pin JP, Naval M, Hernout O, Chrétien F, Chapleur Y, Mathis G (2006) Anal Biochem 385:126CrossRefGoogle Scholar
  44. 44.
    Xu J, Wang X, Ensign B, Li M, Wu L, Guia A, Xu J (2001) Drug Disc Today 6:24CrossRefGoogle Scholar
  45. 45.
    Waggoner A (1976) J Membr Biol 27:317CrossRefGoogle Scholar
  46. 46.
    Loew LM (1988) Spectroscopic membrane probes. CRC Press, FLGoogle Scholar
  47. 47.
    Gonzalez J, Tsien R (1997) Chem Biol 4:269CrossRefGoogle Scholar
  48. 48.
    Luk KC, Hyde EG, Trojanowski JQ, Lee VM (2007) Biochemistry 46:12522CrossRefGoogle Scholar
  49. 49.
    Clemons PA (2004) Curr Opin Chem Biol 8:334CrossRefGoogle Scholar
  50. 50.
    Yarrow JC, Feng Y, Perlman ZE, Kirchhausen T, Mitchison TJ (2003) Comb Chem High Throughput Screen 6:279CrossRefGoogle Scholar
  51. 51.
    Rossi C, Padmanaban D, Ni J, Yeh LA, Glicksman MA, Waldner H (2007) J Biomol Screen 12:481CrossRefGoogle Scholar
  52. 52.
    Hardcastle A, Tomlin P, Norris C, Richards J, Cordwell M, Boxall K, Rowlands M, Jones K, Collins I, McDonald E, Workman P, Aherne W (2007) Mol Cancer Ther 3:1112CrossRefGoogle Scholar
  53. 53.
    Shelat AA, Guy RK (2007) Curr Opin Chem Biol 11:244CrossRefGoogle Scholar
  54. 54.
    Di L, Kerns EH (2006) Drug Disc Today 11:446CrossRefGoogle Scholar
  55. 55.
    Bowes S, Sun D, Kaffashan A, Zeng C, Chuaqui C, Hronowski X, Buko A, Zhang X, Josiah S (2006) J Biomol Screen 11:828CrossRefGoogle Scholar
  56. 56.
    Cheng X, Hochlowski J, Tang H, Hepp D, Beckner C, Kantor S, Schmitt R (2003) J Biomol Screen 8:292CrossRefGoogle Scholar
  57. 57.
    Popa-Burke IG, Issakova O, Arroway JD, Bernasconi P, Chen M, Coudurier L, Galasinski S, Jadhav AP, Janzen WP, Lagaska D, Liu D, Lewis RS, Mohney RP, Sepetov N, Sparkman DA, Hodge CN (2004) Anal Chem 76:7278CrossRefGoogle Scholar
  58. 58.
    Di L, Kerns EH, Chen H, Petusky SL (2006) J Biomol Screen 11:40CrossRefGoogle Scholar
  59. 59.
    Schopfer U, Höhn F, Hueber M, Girod M, Engeloch C, Popov M, Muckenschnabel I (2007) J Biomol Screen 12:724CrossRefGoogle Scholar
  60. 60.
    Archer JR (2004) Assay Drug Dev Technol 2:675CrossRefGoogle Scholar
  61. 61.
    Achyuthan KE, Whitten DG (2007) Comb Chem High Throughput Screen 10:399CrossRefGoogle Scholar
  62. 62.
    Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R (2006) Nat Biotechnol 24:167CrossRefGoogle Scholar
  63. 63.
    Zhang JH, Chung TDY, Oldenburg KR (1999) J Biomol Screen 4:67CrossRefGoogle Scholar
  64. 64.
    Gribbon P, Lyons R, Laflin P, Bradley J, Chambers C, Williams BS, Keighley W, Sewing A (2005) J Biomol Screen 10:99CrossRefGoogle Scholar
  65. 65.
    Zhang XD, Ferrer M, Espeseth AS, Marine SD, Stec EM, Crackower MA, Holder DJ, Heyse JF, Strulovici B (2007) J Biomol Screen 12:497CrossRefGoogle Scholar
  66. 66.
    Landers P (2004) The Wall Street Journal, CCXLII(37)Google Scholar
  67. 67.
    Bender A, Bojanic D, Davies JW, Crisman TJ, Mikhailov D, Scheiber J, Jenkins JL, Deng Z, Hill WA, Popov M, Jacoby E, Glick M (2008) Curr Opin Drug Disc Dev 11:327Google Scholar
  68. 68.
    Kashem MA, Nelson RM, Yingling JD, Pullen SS, Prokopowicz AS, Jones JW, Wolak JP, Rogers GR, Morelock MM, Snow RJ, Homon CA, Jakes S (2006) J Biomol Screen 1:70Google Scholar
  69. 69.
    Fox S (2005) High throughput screening 2005: new users, more cell-based assays, and a host of new tools. HighTech Business Decisions, Moraga, CAGoogle Scholar
  70. 70.
    Burns D (2008) J Biomol Screen 13:695Google Scholar
  71. 71.
    Vaschetto M, Weissbrod T, Bodle D, Guner O (2003) Curr Opin Drug Disc Dev 6:377Google Scholar
  72. 72.
    Hodder P, Mull R, Cassaday J, Berry K, Strulovici B (2004) J Biomol Screen 9:417CrossRefGoogle Scholar
  73. 73.
    Inglese J, Johnson RL, Simeonov A, Xia M, Zheng W, Austin CP, Auld DS (2007) Nat Chem Biol 3:466CrossRefGoogle Scholar
  74. 74.
    Garyantes TK (2002) Drug Disc Today 7:489CrossRefGoogle Scholar
  75. 75.
    Taylor PB, Ashman S, Baddeley SM, Bartram SL, Battle CD, Bond BC, Clements YM, Gaul NJ, McAllister WE, Mostacero JA, Ramon F, Wilson JM, Hertzberg RP, Pope AJ, Macarron R (2002) J Biomol Screen 7:554CrossRefGoogle Scholar
  76. 76.
    Glaser V (2005) Assay Drug Dev Technol 3:607CrossRefGoogle Scholar
  77. 77.
    Ellson R, Stearns R, Mutz M, Brown C, Browning B, Harris D, Qureshi S, Shieh J, Wold D (2005) Comb Chem High Throughput Screen 8:489CrossRefGoogle Scholar
  78. 78.
    Wu G, Irvine J, Luft C, Pressley D, Hodge CN, Janzen B (2003) Comb Chem High Throughput Screen 6:303CrossRefGoogle Scholar
  79. 79.
    Lemmo AV, Hobbs S, Patel P (2004) Assay Drug Dev Technol 2:389CrossRefGoogle Scholar
  80. 80.
    Bartz S, Jackson AL (2005) Science STKE, 2005:39Google Scholar
  81. 81.
    Horrocks C, Halse R, Suzuki R, Shepherd PR (2003) Curr Opin Drug Disc Dev 6:570Google Scholar
  82. 82.
    Miller JL (2006) Curr Top Med Chem 6:19CrossRefGoogle Scholar
  83. 83.
    Card GL, Blasdel L, England BP, Zhang C, Suzuki Y, Gillette S, Fong D, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J, Zhang KY (2005) Nat Biotechnol 2:201CrossRefGoogle Scholar
  84. 84.
    Gogonea V, Suárez D, van der Vaart A, Merz KM (2001) Curr Opin Struct Biol 2:217CrossRefGoogle Scholar
  85. 85.
    Grzybowski BA, Ishchenko AV, Shimada J, Shakhnovich EI (2002) Acc Chem Res 5:261CrossRefGoogle Scholar
  86. 86.
    Editorial (2007) Nat Chem Biol 3:433CrossRefGoogle Scholar
  87. 87.
    Shelat AA, Guy RK (2007) Nat Chem Biol 3:442CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Jeff W. Paslay
    • 1
    Email author
  • John E. Morin
    • 2
  • Richard K. Harrison
    • 3
  1. 1.PhoenixvilleUSA
  2. 2.DoylestownUSA
  3. 3.DowningtownUSA

Personalised recommendations